Signaling of c-kit in dendritic cells influences adaptive immunity

Annals of the New York Academy of Sciences

Volumn 1183, Issue , 2010, Pages 104-122

  Ray, Prabir ^a,b   Krishnamoorthy, Nandini ^a   Oriss, Timothy B ^a   Ray, Anuradha ^a,b  

^a Division of Pulmonary   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Adaptive immunity; C kit; Dendritic cells; Interleukin 6; Jagged 2; Notch; SCF

Indexed keywords

CHOLERA TOXIN; CYCLIC AMP; CYTOKINE; IMATINIB; INTERLEUKIN 6; JANUS KINASE; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN JAGGED2; PROTEIN KINASE B; STAT PROTEIN; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALLERGIC RHINITIS; ASTHMA; B LYMPHOCYTE; CARCINOGENESIS; CARDIOTOXICITY; CELL ACTIVATION; CHRONIC MYELOID LEUKEMIA; CYTOKINE PRODUCTION; DEGRANULATION; DENDRITIC CELL; DERMATOPHAGOIDES; DRUG ACTIVITY; EOSINOPHIL; ERYTHROPOIESIS; GASTROINTESTINAL STROMAL TUMOR; GRANULOCYTE; HEMATOPOIESIS; HUMAN; IMMUNOLOGICAL TOLERANCE; MAST CELL; MELANOGENESIS; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SPERMATOGENESIS; TH1 CELL; TH17 CELL; TH2 CELL;

EID: 75749128594     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05122.x     Document Type: Review

References (170)

1. Besmer, P. et al. 1986. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 320: 415-421.
2. Qiu, F.H. et al. 1988. Primary structure of c-kit: Relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain andCterminus.EMBOJ. 7: 1003-1011.
3. Yarden, Y. et al. 1987. Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 6: 3341-3351.
4. Fantl,W.J., D.E. Johnson & L.T.Williams. 1993. Signaling by receptor tyrosine kinases. Annu. Rev. Biochem. 62: 453-481.
5. Schlessinger, J. 2000. Cell signaling by receptor tyrosine kinases. Cell 103: 211-225.
6. Blume-Jensen, P. & T. Hunter. 2001. Oncogenic kinase signalling. Nature 411: 355-365.
7. Hayashi, S. et al. 1991. Exon skipping by mutation of an authentic splice site of c-kit gene in W/W mouse. Nucleic. Acids. Res. 19: 1267-1271.
8. Reith, A.D. et al. 1991. Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. EMBO J. 10: 2451-2459.
9. Crosier, P.S. et al. 1993. Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acutemyeloid leukemia. Blood 82: 1151-1158.
10. Caruana, G., A.C. Cambareri & L.K. Ashman. 1999. Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts. Oncogene 18: 5573-5581.
11. Besmer, P. 1991. The kit ligand encoded at the murine Steel locus: A pleiotropic growth and differentiation factor. Curr. Opin. Cell. Biol. 3: 939-946.
12. Geissler, E.N. et al. 1991. Stem cell factor (SCF), a novel hematopoietic growth factor and ligand for c-kit tyrosine kinase receptor, maps on human chromosome 12 between 12q14.3 and 12qter. Somat. Cell. Mol. Genet. 17: 207-214.
13. Flanagan, J.G., D.C. Chan & P. Leder. 1991. Transmembrane formof the kit ligand growth factor is determined by alternative splicing and is missing in the Sldmutant. Cell 64: 1025-1035.
14. Toksoz,D. et al. 1992. Support of human hematopoiesis in long-term bone marrow cultures by murine stromal cells selectively expressing the membrane-bound and secreted forms of the human homolog of the steel gene product, stem cell factor. Proc. Natl. Acad. Sci. USA 89: 7350-7354.
15. Huang, E.J. et al. 1992. Differential expression and processing of two cell associated forms of the kit-ligand: KL-1 and KL-2. Mol. Biol. Cell. 3: 349-362.
16. Majumdar, M.K. et al. 1994. Identification and mutation of primary and secondary proteolytic cleavage sites in murine stem cell factor cDNA yields biologically active, cell-associated protein. J. Biol. Chem. 269: 1237-1242.
17. Longley, B.J. et al. 1997. Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc. Natl. Acad. Sci. USA 94: 9017-9021.
18. Reber, L., C.A. Da Silva & N. Frossard. 2006. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur. J. Pharmacol. 533: 327-340.
19. Ali, S. & S. Ali. 2007. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). Gene 401: 38-45.
20. Bernstein, A. et al. 1990. Themouse W/c-kit locus. Ciba Found. Symp. 148: 158-166; discussion 166-172.
21. Miettinen, M. & J. Lasota. 2005. KIT (CD117): A review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl. Immunohistochem. Mol. Morphol. 13: 205-220.
22. Russell, E.S. 1979. Hereditary anemias of the mouse: A review for geneticists. Adv. Genet. 20: 357-459.
23. Cambareri, A.C. et al. 1988. A monoclonal antibody to a human mast cell/myeloid leukaemia-specific antigen binds to normal haemopoietic progenitor cells and inhibits colony formation in vitro. Leuk. Res. 12: 929-939.
24. Ashman, L.K. et al. 1991. Expression of theYB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. Blood 78: 30-37.
25. Ogawa, M. et al. 1991. Expression and function of ckit in hemopoietic progenitor cells. J. Exp. Med. 174: 63-71.
26. Bowie, M.B. et al. 2007. Steel factor responsiveness regulates the high self-renewal phenotype of fetal hematopoietic stem cells. Blood 109: 5043-5048.
27. Ikuta, K. & I.L. Weissman. 1992. Evidence that hematopoietic stem cells express mouse c-kit but do not depend on steel factor for their generation. Proc. Natl. Acad. Sci. USA 89: 1502-1506.
28. Nocka, K. et al. 1990. Candidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors. EMBO J. 9: 3287-3294.
29. Orfao, A. et al. 2007. Recent advances in the understanding of mastocytosis: The role of KIT mutations. Br. J. Haematol. 138: 12-30.
30. Krishnamoorthy, N. et al. 2008. Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma. Nat. Med. 14: 565-573.
31. Metz, M. et al. 2007. Mast cells in the promotion and limitation of chronic inflammation. Immunol. Rev. 217: 304-328.
32. Geissler, E.N., M.A. Ryan & D.E. Housman. 1988. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55: 185-192.
33. Huang, E. et al. 1990. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of theWlocus. Cell 63: 225-233.
34. Kitamura, Y. & S. Go. 1979. Decreased production of mast cells in S1/S1d anemic mice. Blood 53: 492-497.
35. Kitamura, Y., S. Go & K. Hatanaka. 1978. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 52: 447-452.
36. Ray, P. et al. 1991. Ectopic expression of a c-kitW42 minigene in transgenic mice: Recapitulation ofWphenotypes and evidence for c-kit function in melanoblast progenitors. Genes Dev. 5: 2265-2273.
37. Metcalf, D., S. Mifsud & L. Di Rago. 2002. Stem cell factor can stimulate the formation of eosinophils by two types of murine eosinophil progenitor cells. Stem Cells 20: 460-469.
38. Oliveira, S.H. et al. 2002. Stem cell factor induces eosinophil activation and degranulation: Mediator release and gene array analysis. Blood 100: 4291-4297.
39. delRio,M.L. et al. 2008. CX3CR1+ c-kit+ bone marrow cells give rise to CD103+ and CD103-dendritic cells with distinct functional properties. J. Immunol. 181: 6178-6188.
40. Appel, S. et al. 2004. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.[see comment]. Blood 103: 538-544.
41. Dewar, A.L. et al. 2003. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal humanbone marrowprogenitors. Leukemia 17: 1713-1721.
42. Amsen, D. et al. 2004. Instruction of distinct CD4 T helper cell fates by different notch ligands on antigenpresenting cells. Cell 117: 515-526.
43. Amsen, D., A. Antov & R.A. Flavell. 2009. The different faces of Notch in T helper-cell differentiation. Nat. Rev. Immunol. 9: 116-124.
44. Pulendran, B. et al. 1997. Developmental pathways of dendritic cells in vivo: Distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligandtreated mice. J. Immunol. 159: 2222-2231.
45. Feng, B. et al. 2000. Development of mouse dendritic cells fromlineage-negative c-kit(low) pluripotent hemopoietic stem cells in vitro. Stem Cells. 18: 53-60.
46. Lian, Z. et al. 1999. c-kit-low Pluripotent hemopoietic stem cells formCFU-S on day 16. Stem Cells 17: 39-44.
47. Zhang, S.C. & S. Fedoroff. 1998. Modulation of microglia by stem cell factor. J. Neurosci. Res. 53: 29-37.
48. Lassmann, H. 2008. Models of multiple sclerosis: New insights into pathophysiology and repair. Curr. Opin. Neurol. 21: 242-247.
49. Geissmann, F. et al. 2008. Blood monocytes: Distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Immunol. Cell Biol. 86: 398-408.
50. Matos, M.E. et al. 1993. Expression of a functional c-kit receptor on a subset of natural killer cells. J. Exp. Med. 178: 1079-1084.
51. Colucci, F. & J.P. Di Santo. 2000. The receptor tyrosine kinase c-kit provides a critical signal for survival, expansion, and maturation of mouse natural killer cells. Blood 95: 984-991.
52. Borg, C. et al. 2004. Novel mode of action of c-kit tyrosine kinase inhibitors leading toNK cell-dependent antitumor effects. J. Clin. Invest. 114: 379-388.
53. Rodewald, H.R. 2006. Making a Notch in the lymphocyte kit. Eur. J. Immunol. 36: 508-511.
54. Krueger, A., A.I. Garbe & H. von Boehmer. 2006. Phenotypic plasticity of T cell progenitors upon exposure to Notch ligands. J. Exp. Med. 203: 1977-1984.
55. Agosti, V. et al. 2004. Critical role for Kit-mediated Src kinase but not PI 3-kinase signaling in pro T and pro B cell development. J. Exp. Med. 199: 867-878.
56. Brannan, C.I. et al. 1991. Steel-Dickiemutation encodes a c-kit ligand lacking transmembrane and cytoplasmic domains. Proc. Natl. Acad. Sci. USA 88: 4671-4674.
57. Massague, J.&A. Pandiella. 1993.Membrane-anchored growth factors. Annu. Rev. Biochem. 62: 515-541.
58. Kurosawa, K. et al. 1996. Immobilized anti-KIT monoclonal antibody induces ligand-independent dimerization and activation of Steel factor receptor: Biologic similarity with membrane-bound form of Steel factor rather than its soluble form. Blood 87: 2235-2243.
59. Miyazawa, K. et al. 1995.Membrane-bound Steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form. Blood 85: 641-649.
60. Mierke, C.T. et al. 2000. Human endothelial cells regulate survival and proliferation of human mast cells. J. Exp. Med. 192: 801-811.
61. Sun, L., J. Lee & H.A. Fine. 2004. Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury. J. Clin. Invest. 113: 1364-1374.
62. Corless, C.L. et al. 2004. KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors. J. Mol. Diagn. 6: 366-370.
63. Theou-Anton, N. et al. 2006. Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism. Br. J. Cancer. 94: 1180-1185.
64. Lennartsson, J. & L. Ronnstrand. 2006. The stem cell factor receptor/c-Kit as a drug target in cancer. Curr. Cancer Drug Targets 6: 65-75.
65. Lennartsson, J. et al. 2005.Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells (Dayton, Ohio) 23: 16-43.
66. Kent, D. et al. 2008. Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway. Clin. Cancer Res. 14: 1926-1930.
67. Fiuza, U.M. & A.M. Arias. 2007. Cell and molecular biology of Notch. J. Endocrinol. 194: 459-474.
68. Maillard, I., T. Fang & W.S. Pear. 2005. Regulation of lymphoid development, differentiation, and function by the Notch pathway. Annu. Rev. Immunol. 23: 945-974.
69. Giudicelli, F. & J. Lewis. 2004. The vertebrate segmentation clock. Curr. Opin. Genet Dev. 14: 407-414.
70. Palmeirim, I. et al. 1997. Avian hairy gene expression identifies a molecular clock linked to vertebrate segmentation and somitogenesis. Cell 91: 639-648.
71. Klein, T., K. Brennan & A.M. Arias. 1997. An intrinsic dominant negative activity of serrate that is modulated during wing development in Drosophila. Dev. Biol. 189: 123-134.
72. Micchelli, C.A., E.J. Rulifson & S.S. Blair. 1997. The function and regulation of cut expression on the wing margin of Drosophila: Notch, Wingless and a dominant negative role for Delta and Serrate. Development (Cambridge, England) 124: 1485-1495.
73. Ladi, E. et al. 2005. The divergent DSL ligand Dll3 does not activateNotch signaling but cell autonomously attenuates signaling induced by other DSL ligands. J. Cell Biol. 170: 983-992.
74. Lowell, S. et al. 2000. Stimulation of human epidermal differentiation by delta-notch signalling at the boundaries of stem-cell clusters. Curr. Biol. 10: 491-500.
75. Sakamoto, K. et al. 2002. Intracellular cell-autonomous association of Notch and its ligands: A novel mechanism of Notch signalmodification. Dev. Biol. 241: 313-326.
76. Massa, S. et al. 2006. Critical role for c-kit (CD117) in T cell lineage commitment and early thymocyte development in vitro. Eur. J. Immunol. 36: 526-532.
77. Hozumi, K. et al. 2004. Delta-like 1 is necessary for the generation of marginal zone B cells but not T cells in vivo. Nat. Immunol. 5: 638-644.
78. Carnahan, J.F., D.R. Patel & J.A. Miller. 1994. Stem cell factor is a neurotrophic factor for neural crest-derived chick sensory neurons. J. Neurosci. 14: 1433-1440.
79. Jin, K. et al. 2002. Stem cell factor stimulates neurogenesis in vitro and in vivo. J. Clin. Invest. 110: 311-319.
80. Das, A.V. et al. 2004. Identification of c-Kit receptor as a regulator of adult neural stem cells in the mammalian eye: Interactions with Notch signaling. Dev. Biol. 273: 87-105.
81. Schaller, M.A. et al. 2007. Notch ligand Delta-like 4 regulates disease pathogenesis during respiratory viral infections by modulating Th2 cytokines. J. Exp. Med. 204: 2925-2934.
82. Blazquez, A.B. & M.C. Berin. 2008. Gastrointestinal dendritic cells promote Th2 skewing via OX40L. J. Immunol. 180: 4441-4450.
83. Krawczyk,C.M., J. Sun&E.J.Pearce. 2008.Th2differentiation is unaffected by Jagged2 expression on dendritic cells. J. Immunol. 180: 7931-7937.
84. Worsley, A.G. et al. 2008. Dendritic cell expression of the Notch ligand jagged2 is not essential for Th2 response induction in vivo. Eur. J. Immunol. 38: 1043-1049.
85. Tanaka, S. et al. 2006. The interleukin-4 enhancer CNS-2 is regulated by Notch signals and controls initial expression in NKT cells and memory-type CD4 T cells. Immunity 24: 689-701.
86. Skokos, D. & M.C. Nussenzweig. 2007. CD8-DCs induce IL-12-independent Th1 differentiation through Delta 4 Notch-like ligand in response to bacterial LPS. J. Exp. Med. 204: 1525-1531.
87. Bruckner, K. et al. 2000. Glycosyltransferase activity of Fringe modulates Notch-Delta interactions. Nature 406: 411-415.
88. Moloney, D.J. et al. 2000. Fringe is a glycosyltransferase that modifies Notch. Nature 406: 369-375.
89. Houde, C. et al. 2004. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 104: 3697-3704.
90. Takeuchi, T., Y. Adachi & Y. Ohtsuki. 2005. Skeletrophin, a novel ubiquitin ligase to the intracellular region of Jagged-2, is aberrantly expressed inmultiple myeloma. Am. J. Pathol. 166: 1817-1826.
91. Bataille, R. et al. 2008. CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. Leuk. Res. 32: 379-382.
92. Montero, J.C. et al. 2008. Expression of c-Kit isoforms inmultiplemyeloma: Differences in signaling and drug sensitivity. Haematologica 93: 851-859.
93. Dispenzieri, A. et al. 2006. A phase II trial of imatinib in patients with refractory/relapsed myeloma. Leuk. Lymph. 47: 39-42.
94. Tsai, S., J. Fero & S. Bartelmez. 2000. Mouse Jagged2 is differentially expressed in hematopoietic progenitors and endothelial cells and promotes the survival and proliferation of hematopoietic progenitors by direct cell-to-cell contact. Blood 96: 950-957.
95. DeHart, S.L., M.J. Heikens & S. Tsai. 2005. Jagged2 promotes the development of natural killer cells and the establishment of functional natural killer cell lines. Blood 105: 3521-3527.
96. Jiang, R. et al. 1998. Defects in limb, craniofacial, and thymic development in Jagged2 mutant mice. Genes Dev. 12: 1046-1057.
97. Kared, H. et al. 2006. Jagged2-expressing hematopoietic progenitors promote regulatory T cell expansion in the periphery through notch signaling. Immunity 25: 823-834.
98. Hoyne, G.F. et al. 2000. Serrate1-induced notch signalling regulates the decision between immunity and tolerance made by peripheral CD4(+) T cells. Int. Immunol. 12: 177-185.
99. Shimizu, K. et al. 2000. Binding of Delta1, Jagged1, and Jagged2 to Notch2 rapidly induces cleavage, nuclear translocation, and hyperphosphorylation of Notch2. Mol. Cell. Biol. 20: 6913-6922.
100. Blume-Jensen, P., R. Janknecht & T. Hunter. 1998. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr. Biol. 8: 779-782.
101. Nocka, K. et al. 1989. Expression of c-kit gene products in known cellular targets ofWmutations in normal and W mutant mice-evidence for an impaired c-kit kinase in mutant mice. Genes Dev. 3: 816-826.
102. Tan, J.C. et al. 1990. The dominant W42 spotting phenotype results from a missense mutation in the c-kit receptor kinase. Science 247: 209-212.
103. Serve, H., Y.C. Hsu & P. Besmer. 1994. Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. J. Biol. Chem. 269: 6026-6030.
104. Hashimoto, K. et al. 2003.Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation. Blood 101: 1094-1102.
105. Ronnstrand, L. 2004. Signal transduction via the stem cell factor receptor/c-Kit. Cell. Mol. Life Sci. 61: 2535-2548.
106. Pello, O.M. et al. 2006. SOCS up-regulation mobilizes autologous stem cells through CXCR4 blockade. Blood 108: 3928-3937.
107. Kohl, T.M. et al. 2005. KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood 105: 3319-3321.
108. Timokhina, I. et al. 1998. Kit signaling through PI 3-kinase and Src kinase pathways: An essential role for Rac1 and JNK activation in mast cell proliferation. EMBO J. 17: 6250-6262.
109. Gibbons, S.J. et al. 2003. Kit/stem cell factor receptorinduced phosphatidylinositol 3'-kinase signalling is not required for normal development and function of interstitial cells of Cajal in mouse gastrointestinal tract. Neurogastroenterol. Motil. 15: 643-653.
110. Rottapel, R. et al. 2002. The tumor suppressor activity of SOCS-1. Oncogene 21: 4351-4362.
111. Bayle, J. et al. 2004. Suppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signaling. J. Biol. Chem. 279: 12249-12259.
112. Helgason, C.D. et al. 1998. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 12: 1610-1620.
113. Huber, M. et al. 1998. Targeted disruption of SHIP leads to Steel factor-induced degranulation of mast cells. EMBO J. 17: 7311-7319.
114. Zhang, Y.Y. et al. 1998. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J. Exp. Med. 187: 1893-1902.
115. Sattler, M. et al. 1997. Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL). J. Biol. Chem. 272: 10248-10253.
116. Huang, S. et al. 1996. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 13: 2339-2347.
117. Hou, L., J.J. Panthier & H. Arnheiter. 2000. Signaling and transcriptional regulation in the neural crestderived melanocyte lineage: Interactions between KIT and MITF. Development 127: 5379-5389.
118. Leslie,M.C. & M. Bar-Eli. 2005. Regulation of gene expression in melanoma: New approaches for treatment. J. Cell. Biochem. 94: 25-38.
119. Poole, D.P. et al. 2004. Protein kinases expressed by interstitial cells of Cajal. Histochem. Cell. Biol. 121: 21-30.
120. Shaw, T.J. et al. 2002. Cyclic AMP in ovarian cancer cells both inhibits proliferation and increases c-KIT expression. Exp. Cell. Res. 273: 95-106.
121. Grimaldi, P. et al. 2003. Cyclic adenosine monophosphate (cAMP) stimulation of the kit ligand promoter in sertoli cells requires an Sp1-binding region, a canonical TATA box, and a cAMP-induced factor binding to an immediately downstream GC-rich element. Biol. Reprod. 69: 1979-1988.
122. Janeway, C.A., Jr.&R.Medzhitov. 2002. Innateimmune recognition. Annu. Rev. Immunol. 20: 197-216.
123. Kapsenberg, M.L. 2003. Dendritic-cell control of pathogen-drivenT-cell polarization.Nat.Rev Immunol. 3: 984-993.
124. Braun, M.C. et al. 1999. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression. J. Exp. Med. 189: 541-552.
125. Bagley, K.C. et al. 2002. Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway. Infect. Immun. 70: 5533-5539.
126. de Jong, E.C. et al. 2002. Microbial compounds selectively induce Th1 cell-promoting or Th2 cellpromoting dendritic cells in vitro with diverse th cellpolarizing signals. J. Immunol. 168: 1704-1709.
127. Kalinski, P. et al. 2003. Analysis of the CD4-T cell responses to house dust mite allergoid. Allergy 58: 648-656.
128. Acosta-Rodriguez, E.V. et al. 2007. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8: 942-949.
129. Bettelli, E. et al. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
130. Eisenbarth, S.C., S. Cassel & K. Bottomly. 2004. Understanding asthma pathogenesis: Linking innate and adaptive immunity. Curr. Opin. Pediatr. 16: 659-666.
131. Wang, H. et al. 2005. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T cell tolerance. Blood 105: 1135-1143.
132. Fukao, T. et al. 2002. PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat. Immunol. 3: 875-881.
133. La Flamme, A.C., A.S. MacDonald & E.J. Pearce. 2000. Role of IL-6 in directing the initial immune response to schistosome eggs. J. Immunol. 164: 2419-2426.
134. Dienz, O. & M. Rincon. 2009. The effects of IL-6 on CD4 T cell responses. Clin. Immunol. 130: 27-33.
135. Hambardzumyan,D.,O.J.Becher&E.C.Holland. 2008. Cancer stem cells and survival pathways. Cell Cycle 7: 1371-1378.
136. Gu,H. et al. 2001. Essential role for Gab2 in the allergic response. Nature 412: 186-190.
137. Dorsey, J.F. et al. 2002. Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2. Blood 99: 1388-1397.
138. Schulz,O. et al. 2000. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 13: 453-462.
139. Soong, L. et al. 1996. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 4: 263-273.
140. Patton, D.T. et al. 2006. Cutting edge: The phosphoinositide 3-kinase p110 delta is critical for the function ofCD4+CD25+Foxp3+regulatoryTcells. J. Immunol. 177: 6598-6602.
141. Okkenhaug, K. et al. 2002. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297: 1031-1034.
142. Eisen-Vandervelde, A.L. et al. 2004. Hepatitis C virus core selectively suppresses interleukin-12 synthesis in human macrophages by interfering with AP-1 activation. J. Biol. Chem. 279: 43479-43486.
143. Liu, J., M. Chen & X. Wang. 2000. Calcitonin gene-related peptide inhibits lipopolysaccharideinduced interleukin-12 release from mouse peritoneal macrophages, mediated by the cAMP pathway. Immunology 101: 61-67.
144. Meeran, S.M., T. Punathil & S.K. Katiyar. 2008. IL-12 deficiency exacerbates inflammatory responses in UVirradiated skin and skin tumors. J. Invest. Dermatol. 128: 2716-2727.
145. Lesinski, G.B. et al. 2004. IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma. J. Immunol. 172: 7368-7376.
146. Aggarwal, B.B. et al. 2006. Targeting signal-transducerand-activator-of- transcription-3 for prevention and therapy of cancer: Modern target but ancient solution. Ann. N. Y. Acad. Sci. 1091: 151-169.
147. Ganesan, L.P. et al. 2006. FcgammaR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways. Blood 108: 718-725.
148. Zhang, J., Y. Li & B. Shen. 2003. PI3-K/Akt pathway contributes to IL-6-dependent growth of 7TD1 cells. Cancer Cell. Int. 3: 1.
149. Iezzi, G. et al. 2009. CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells. Proc. Natl. Acad. Sci. USA 106: 876-881.
150. Oriss, T.B. et al. 2005. Dynamics of dendritic cell phenotype and interactions with CD4+ T cells in airway inflammation and tolerance. J. Immunol. 174: 854-863.
151. Tam, S.Y. et al. 2004. RabGEF1 is a negative regulator of mast cell activation and skin inflammation. Nat. Immunol. 5: 844-852.
152. Kalesnikoff, J. et al. 2006. RabGEF1 regulates stem cell factor/c-Kit-mediated signaling events and biological responses in mast cells. Proc. Natl. Acad. Sci. USA 103: 2659-2664.
153. Demetri, G.D. et al. 2002. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.[ see comment]. N. Engl. J. Med. 347: 472-480.
154. Fletcher, J.A. & B.P. Rubin. 2007. KIT mutations in GIST. Curr. Opin. Genet. Dev. 17: 3-7.
155. Rubin, B.P. et al. 2001. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61: 8118-8121.
156. Druker, B.J. 2002. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol. Med. 8: S14-18.
157. Fernandez, A. et al. 2007. Rational drug redesign to overcome drug resistance in cancer therapy: Imatinib moving target. Cancer Res. 67: 4028-4033.
158. Berlin, A.A. et al. 2004. Inhibition of stem cell factor reduces pulmonary cytokine levels during allergic airway responses.[see comment]. Clin. Exp. Immunol. 136: 15-20.
159. Berlin, A.A., C.M. Hogaboam & N.W. Lukacs. 2006. Inhibition of SCF attenuates peribronchial remodeling in chronic cockroach allergen-induced asthma. Lab. Invest. 86: 557-565.
160. Campbell, E. et al. 1999. Stem cell factor-induced airway hyperreactivity in allergic and normal mice. Am. J. Pathol. 154: 1259-1265.
161. Lukacs, N.W. et al. 1996. The role of stemcell factor (ckit ligand) and inflammatory cytokines in pulmonary mast cell activation. Blood 87: 2262-2268.
162. Lukacs, N.W. et al. 1996. Stem cell factor (c-kit ligand) influences eosinophil recruitment and histamine levels in allergic airway inflammation. J. Immunol. 156: 3945-3951.
163. Oliveira, S.H. & N.W. Lukacs. 2003. Stem cell factor: A hemopoietic cytokine with important targets in asthma. Curr. Drug Targets -Inflamm. Allergy 2: 313-318.
164. Juurikivi, A. et al. 2005. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia:Apotential approach to the treatment of arthritis. Ann. Rheum. Dis. 64: 1126-1131.
165. Haraoui, B. 2005. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis. J. Rheumatol. -Supplement 72: 46-47.
166. Steinman, R.M. 2008. Dendritic cells in vivo: A key target for a new vaccine science. Immunity 29: 319-324.
167. Vredevoe, D.L. et al. 2004. Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure. Am. J. Cardiol. 93: 1007-1011.
168. Maekawa, Y. et al. 2003. Delta1-Notch3 interactions bias the functional differentiation of activated CD4+ T cells. Immunity 19: 549-559.
169. Minter, L.M. et al. 2005. Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nat. Immunol. 6: 680-688.
170. Ray, A. & K.E. Prefontaine. 1994. Physical association and functional antagonism between the p65 subunit of transcription factorNF-kappa B and the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA 91: 752-756.